Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4485 Inpatient admissions for hormone secretion management in patients with neuroendocrine neoplasms (NEN) treated with [177Lu]Lu-DOTA-Octreotate (LuTate) therapy over a 4.5 year period at a single high volume treatment centre

Introduction: LuTate therapy is an effective treatment for patients with somatostatin receptor expressing NEN. However, patients (pts) with functional tumours may develop an acute flare of symptoms during or after PRRT.

Conference:

Presenting Author: Kong G

Authors: Neeson L, Boehm E, Chiang C, Michael M, Sachithanandan N,

Keywords: PRRT, NET, high-risk, flare, outcomes, NEN, single centre,

#4450 Management of grade I metastatic pancreatic neuroendocrine tumours: A case report and literature review

Introduction: Grade I neuroendocrine tumours (NETs) represent a distinct clinico-histological entity that requires a tailored management approach. The treatment of these tumours has evolved, but challenges remain, especially in regions with limited access to nuclear medicine imaging.

Conference:

Presenting Author:

Authors: Boudersa A, Kouadri N, Bouguettaya A,

Keywords: NET, grade 1, somatulin,

#4340 Predominant volumetric phenotype in dual PET and overall survival in NENs

Introduction: Dual 18F-FDG/68Ga-DOTATATE PET can predict NEN prognosis and guide treatment choice. However, research to date (such as the NEPTET score) has focused on the dual PET phenotype of single-point lesions rather than of the total disease volume.

Conference:

Presenting Author: Chan D

Authors: Chan D, Bernard E, Mokhtar S, Chou A, Gill A,

Keywords: Prognostic biomarker, PET/CT, tumour volume, 18F-FDG, 68Ga-DOTATATE,

#4339 Dual threshold contouring for [68Ga]DOTATATE PET and correlation with overall survival (OS) in patients with neuroendocrine neoplasia (NEN)

Introduction: Accurate contouring for [68Ga]DOTATATE PET in NEN is challenging due to differing physiological uptake for the liver, spleen and other organs. This poses a significant problem for absolute thresholding algorithms using a single threshold, even if the threshold is based on liver uptake (as suggested for FDG PET by PERCIST). Improved contouring of PET to measure [68Ga]DOTATATE-avid tumour volume could help clinical translation of this potential biomarker.

Conference:

Presenting Author: Chan D

Authors: Chan D, Mokhtar S, Bernard E, Diakos C, Sabahi Z,

Keywords: prognostic biomarker, PET imaging, [68Ga]DOTATATE, Total Lesion Volume,

#4050 PET/CT imaging of the somatostatin receptor with [18F]AlF-NOTA-octreotide PET/CT: Analysis of impact on tumor staging and therapeutic management

Introduction: [18F]AlF-NOTA-octreotide ([18F]AlF-OC) is a promising alternative for [68Ga]Ga-DOTA-somatostatin analogues (SSAs) in PET imaging of the somatostatin receptor (SST).

Conference:

Presenting Author: Leupe H

Authors: Leupe H, Vandamme T, van den Broeck B, Lybaert W, Dekervel J,

Keywords: Neuroendocrine tumor, nuclear medicine, PET imaging, somatostatin receptor, [68Ga]Ga-DOTA-SSA, [18F]AlF-NOTA-octreotide,